Do I qualify for this research study?

This study is for patients with prostate cancer that has spread beyond the prostate, -AND- progressed despite medical treatment to reduce male hormones, -AND- have received ONLY ONE previous ARAT hormone treatment (with enzalutamide, abiraterone, darolutamide, or apalutamide), and who did NOT receive chemotherapy, do not want to receive chemotherapy, or are not eligible to receive chemotherapy.   

    There is no chemotherapy administered during this study. Please note that ARAT (Androgen Receptor-Axis-Targeted Therapy) hormone therapy with enzalutamide, abiraterone, darolutamide, apalutamide -AND- medical treatments to reduce male hormones are NOT chemotherapy.  

     

    Please answer the following questions to determine if you are a potential candidate for this research study.  

     

    Once you submit your responses to the eligibility questions below, you will be notified as to whether you meet the criteria required for this research study.  

     

    If you are not sure about answering a question, please bookmark this website and check your medical records before answering these questions.

  • Do you have prostate cancer that has spread beyond the prostate -AND- has progressed despite previous treatment with hormone therapy with any of these agents: enzalutamide, abiraterone, darolutamide, apalutamide?

  • Have you received chemotherapy (i.e., docetaxel, cabazitaxel)?

  • Have you been treated with more than one ARAT hormone therapy with any of these agents: enzalutamide, abiraterone, darolutamide, apalutamide?